文献速递前列腺癌

瑞典局部晚期前列腺癌治疗与死亡率变化:2000-2016年全国人群研究

Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in Sweden.
PubMed 文献 · BJU Int · 2020-05-08

根治性治疗比例从2000-2003年的15%升至2012-2016年的43%,同期5年前列腺癌死亡率从19%降至15%,65-74岁男性降幅最大(16%至8%)。多因素分析显示<80岁男性最后时段较第一时段前列腺癌死亡风险HR为0.65(95%CI 0.56-0.76)。

要点

  • 局部晚期前列腺癌根治性治疗比例从15%增至43%,同期5年前列腺癌死亡率从19%降至15%。
  • 65-74岁男性5年前列腺癌死亡率降幅最大,从16%降至8%。
  • <80岁男性最后时段较第一时段前列腺癌死亡风险HR为0.65(95%CI 0.56-0.76)。

核心结论

  • 根治性治疗使用增加三倍伴随所有新诊断局部晚期前列腺癌男性前列腺癌死亡率适度下降。
  • 65-74岁男性前列腺癌死亡相对风险下降50%,提示随机试验中的获益可在真实环境中实现。

研究设计与样本

  • 采用竞争风险分析评估所有局部晚期前列腺癌男性的累积前列腺癌死亡率,多因素回归分析计算全因和前列腺癌特异性死亡的风险比(HR)。

主要发现

  • 接受原发性根治性放疗(n=4174)或前列腺切除术(n=1210)的比例从2000-2003年的15%、2004-2007年的25%、2008-2011年的33%升至2012-2016年的43%。
  • 所有男性5年前列腺癌死亡率从19%、18%、17%降至15%,65-74岁男性从16%降至8%。
  • <80岁男性最后时段较第一时段前列腺癌死亡风险HR为0.65(95%CI 0.56-0.76)。

临床怎么用

  • 局部晚期前列腺癌男性可从根治性治疗中获益,真实世界数据支持随机试验结论。
  • 65-74岁男性根治性治疗相关的前列腺癌死亡风险下降尤为显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether the effects of radical treatment in men with locally advanced prostate cancer (PCa) on PCa mortality observed in randomised clinical trials are applicable on a population basis. PATIENTS AND METHODS: We conducted a population-based cohort study using the Prostate Cancer data Base Sweden of 20 350 men diagnosed between 2000 and 2016 with locally advanced PCa, defined as clinical local stage T3/T4, M0, Mx and a prostate-specific antigen level of <100 ng/mL. Cumulative PCa mortality was examined using competing risk analysis of all men with locally advanced PCa, and also including men who did not undergo radical treatment. Multivariate regression analysis, including prognostic factors, was used to calculate hazard ratios (HRs) for all-cause and PCa-specific death. RESULTS: The proportion of men treated with primary radical radiotherapy (n = 4174) or prostatectomy (n = 1210) increased from 15% in 2000-2003, 25% in 2004-2007, 33% in 2008-2011 to 43% in 2012-2016. The corresponding 5-year PCa mortality decreased from 19%, 18%, 17%, to 15% for all men, with the steepest decrease in men aged 65-74 years, from 16% to 8%. The risk of PCa mortality in men aged <80 years was lower in the last period compared to the first period, with a HR of 0.65 (95% confidence interval 0.56-0.76) in multivariate analysis. CONCLUSIONS: The threefold increase in use of radical treatment was accompanied by a modest decrease in PCa mortality in all men with newly diagnosed locally advanced PCa. For men aged 65-74 years, there was a 50% decrease in the relative risk of PCa death. This indicates that the benefits previously observed in randomised trials can also be achieved in a real-life setting.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Orrason AW, Westerberg M, Garmo H, et al. Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in Sweden. BJU Int. 2020. PMID: 32274889. doi:10.1111/bju.15077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。